Atossa Therapeutics (ATOS) 10-Q 13 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 09, 2019
Document Information [Line Items]
Entity Registrant Name	ATOSSA GENETICS INC
Entity Central Index Key	0001488039
Trading Symbol	atos
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		9,129,563
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 17,058,527	$ 10,380,493
Restricted cash	110,000	110,000
Prepaid expenses	813,168	509,833
Research and development tax rebate receivable	406,306	518,098
Other current assets	140	30,942
Total current assets	18,388,141	11,549,366
Furniture and equipment, net	44,174	54,487
Intangible assets, net	83,958	99,375
Right-of-use asset	75,822
Other assets	17,218	17,218
Total Assets	18,609,313	11,720,446
Current liabilities
Accounts payable	318,266	353,328
Accrued expenses	53,485	177,074
Payroll liabilities	589,445	935,070
Stock-based compensation liability		1,410,025
Lease liability	51,795
Other current liabilities	19,838	39,939
Total current liabilities	1,032,829	2,915,436
Long term liabilities
Lease liability long term	24,027
Total Liabilities	1,056,856	2,915,436
Commitments and contingencies (note 11)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized; 676 and 2,379 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively	1	2
Additional paid-in capital- Series B convertible preferred stock	675,999	2,378,997
Common stock - $0.18 par value; 175,000,000 shares authorized, and 9,129,563 and 5,846,552 shares issued and outstanding, as of June 30, 2019 and December 31, 2018, respectively	1,643,309	1,052,372
Additional paid-in capital	103,400,247	82,204,902
Accumulated deficit	(88,167,099)	(76,831,263)
Total Stockholders' Equity	17,552,457	8,805,010
Total Liabilities and Stockholders' Equity	$ 18,609,313	$ 11,720,446

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	676	2,379
Preferred stock, outstanding (in shares)	676	2,379
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000,000	175,000,000
Common stock, issued (in shares)	9,129,563	5,846,552
Common stock, outstanding (in shares)	9,129,563	5,846,552

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Operating expenses
Research and development	$ 2,611,948	$ 1,467,736	$ 4,063,184	$ 1,938,712
General and administrative	4,674,121	2,674,920	7,287,214	4,078,385
Total operating expenses	7,286,069	4,142,656	11,350,398	6,017,097
Operating loss	(7,286,069)	(4,142,656)	(11,350,398)	(6,017,097)
Other income	23,540	79	14,562	138
Loss before income taxes	(7,262,529)	(4,142,577)	(11,335,836)	(6,016,959)
Income taxes
Net loss	(7,262,529)	(4,142,577)	(11,335,836)	(6,016,959)
Deemed dividend attributable to preferred stock		(11,479,308)		(11,479,308)
Net loss applicable to common shareholders	$ (7,262,529)	$ (15,621,885)	$ (11,335,836)	$ (17,496,267)
Net loss per share of common stock, basic and diluted: (in dollars per share)	$ (0.80)	$ (5.08)	$ (1.44)	$ (6.11)
Weighted average shares outstanding - basic and diluted (in shares)	9,126,153	3,073,803	7,852,907	2,864,033

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017			2,651,952
Balance at Dec. 31, 2017			$ 477,342	$ 71,887,674	$ (65,426,329)	$ 6,938,687
Amortization of commitment shares				(19,852)		(19,852)
Compensation cost for stock options granted				215,139		215,139
Net loss					(1,874,382)	(1,874,382)
Balance (in shares) at Mar. 31, 2018			2,651,952
Balance at Mar. 31, 2018			$ 477,342	72,082,961	(67,300,711)	5,259,592
Balance (in shares) at Dec. 31, 2017			2,651,952
Balance at Dec. 31, 2017			$ 477,342	71,887,674	(65,426,329)	6,938,687
Amortization of commitment shares						(39,703)
Net loss						(6,016,959)
Balance (in shares) at Jun. 30, 2018	5,802		4,874,099
Balance at Jun. 30, 2018	$ 6	5,801,994	$ 877,329	78,330,724	(71,443,288)	13,566,765
Balance (in shares) at Mar. 31, 2018			2,651,952
Balance at Mar. 31, 2018			$ 477,342	72,082,961	(67,300,711)	5,259,592
Amortization of commitment shares				(19,851)		(19,851)
Compensation cost for stock options granted				179,050		179,050
Net loss					(4,142,577)	(4,142,577)
Issuance of stock and warrants, net of issuance costs (in shares)	13,624
Issuance of Series B convertible preferred stock and warrants, net of issuance costs of $1,333,449	$ 14	6,926,778		5,363,759		12,290,551
Allocation of Series B convertible preferred stock to beneficial conversion feature		(4,782,100)		4,782,100
Deemed dividend on Series B convertible preferred stock		11,479,308		(11,479,308)
Conversion of Series B convertible preferred stock to common stock (in shares)	(7,822)
Conversion of Series B convertible preferred stock to common stock	$ (8)
Conversion of Series B convertible preferred stock to common stock		(7,821,992)	$ 399,987	7,422,013
Conversion of Series B convertible preferred stock to common stock (in shares)			2,222,147
Balance (in shares) at Jun. 30, 2018	5,802		4,874,099
Balance at Jun. 30, 2018	$ 6	5,801,994	$ 877,329	78,330,724	(71,443,288)	13,566,765
Balance (in shares) at Dec. 31, 2018	2,379		5,846,552
Balance at Dec. 31, 2018	$ 2	2,378,997	$ 1,052,372	82,204,902	(76,831,263)	8,805,010
Compensation cost for stock options granted				275,833		275,833
Net loss					(4,073,307)	(4,073,307)
Conversion of Series B convertible preferred stock to common stock (in shares)	(1,677)
Conversion of Series B convertible preferred stock to common stock	$ (1)
Conversion of Series B convertible preferred stock to common stock		(1,676,998)	$ 85,753	1,591,246
Conversion of Series B convertible preferred stock to common stock (in shares)			476,431
Balance (in shares) at Mar. 31, 2019	702		9,122,171
Balance at Mar. 31, 2019	$ 1	701,999	$ 1,641,979	98,056,781	(80,904,570)	$ 19,496,190
Issuance of common stock upon warrant exercise (in shares)			2,799,188			2,800,000
Issuance of common stock upon warrant exercise			$ 503,854	10,832,856		$ 11,336,710
Reclassification of stock-based compensation liability upon option cancellation				3,151,944		3,151,944
Balance (in shares) at Dec. 31, 2018	2,379		5,846,552
Balance at Dec. 31, 2018	$ 2	2,378,997	$ 1,052,372	82,204,902	(76,831,263)	8,805,010
Amortization of commitment shares
Net loss						(11,335,836)
Balance (in shares) at Jun. 30, 2019	676		9,129,563
Balance at Jun. 30, 2019	$ 1	675,999	$ 1,643,309	103,400,247	(88,167,099)	17,552,457
Balance (in shares) at Mar. 31, 2019	702		9,122,171
Balance at Mar. 31, 2019	$ 1	701,999	$ 1,641,979	98,056,781	(80,904,570)	19,496,190
Compensation cost for stock options granted				5,318,796		5,318,796
Net loss					(7,262,529)	(7,262,529)
Conversion of Series B convertible preferred stock to common stock (in shares)	(26)
Conversion of Series B convertible preferred stock to common stock
Conversion of Series B convertible preferred stock to common stock		(26,000)	$ 1,330	24,670
Conversion of Series B convertible preferred stock to common stock (in shares)			7,392
Balance (in shares) at Jun. 30, 2019	676		9,129,563
Balance at Jun. 30, 2019	$ 1	$ 675,999	$ 1,643,309	$ 103,400,247	$ (88,167,099)	$ 17,552,457

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)	3 Months Ended
	Jun. 30, 2018USD ($)
Issuance of Series B convertible preferred stock and warrants, issuance costs	$ 1,333,449

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudied) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,142,577)	$ (11,335,836)	$ (6,016,959)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted		5,594,629	394,189
Disposal of assets		5,806
Depreciation and amortization		27,549	17,838
Change in fair value of stock-based compensation liability		1,741,919	1,557,163
Changes in operating assets and liabilities:
Prepaid expenses		(303,335)	(189,445)
Research and development tax rebate receivable		111,792	(267,734)
Other assets		30,802	56,644
Accounts payable		(35,062)	(143,684)
Payroll liabilities		(345,625)	167,790
Accrued expenses		(123,589)	196,608
Other current liabilities		(20,101)	7,797
Net cash used in operating activities		(4,651,051)	(4,219,793)
CASH FLOWS FROM INVESTING ACTIVITY
Purchase of furniture and equipment		(7,625)	(51,491)
Net cash used in investing activities		(7,625)	(51,491)
CASH FLOWS FROM FINANCING ACTIVITY
Proceeds from issuance of Series B convertible preferred stock and warrants, net of issuance costs			12,290,551
Proceeds from exercise of warrants		11,336,710
Net cash provided by financing activities		11,336,710	12,290,551
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH		6,678,034	8,019,267
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE		10,490,493	7,272,469
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	15,291,736	17,168,527	15,291,736
SUPPLEMENTAL DISCLOSURES
Cash and cash equivalents	15,236,736	17,058,527	15,236,736
Restricted cash	55,000	110,000	55,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	15,291,736	17,168,527	15,291,736
NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of stock-based liability awards to equity upon cancellation		3,151,944
Amortization of commitment shares	$ 19,851		$ 39,703

Note 1 - Nature of Operations

Note 1 - Nature of Operations	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1: Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 December 31.

Note 2 - Liquidity and Capital

Note 2 - Liquidity and Capital Resources	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2: The Company has incurred net losses and negative operating cash flows since inception. For the six June 30, 2019, $11.3 $4.7 June 30, 2019, $17.1 $17.4 not one not may not may

Note 3 - Summary of Accounting

Note 3 - Summary of Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 -Q and Rule 10 - 01 of Regulation S- X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10 -K of the Company for the year ended December 31, 2018. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2019, are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Recently Adopted Accounting Pronouncements: In the first quarter of 2019, we adopted Accounting Standards Update (“ASU”) No. 2016 - 02, Lease Accounting Topic 842 : (" Topic 842 ") and recognized on our Condensed Consolidated Balance Sheet $101,000 of lease liabilities with corresponding right-of-use assets for operating leases. The new lease standard requires a lessee to measure its operating lease liabilities at the present value of the remaining minimum lease payments with a discounted cash flow model using the interest rate implicit in the lease. If the implicit interest rate cannot be readily determined, the lessee must use its incremental borrowing rate (“IBR”). If the lessee does not have an IBR, the lessee must use a rate that approximates the rate of interest that the lessee would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. The implicit interest rate was readily determinable for our copier lease; however, we used an IBR to measure our adoption date operating lease liability related to our office space which rate represents our estimated borrowing rate on a secured loan collateralized by similar assets for a similar term. The adoption did not have a material impact on the Company's consolidated financial statements. As permitted under the standard, we elected prospective application of the new guidance and prior periods continue to be presented in accordance with Accounting Standards Codification ("ASC") Topic 840. Refer to our 2018 Annual Report on Form 10 -K for disclosures required by Topic 840. The new standard provides a number of optional practical expedients in transition. We elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, to not separate lease and non lease components and to not reassess initial direct costs. We did not elect the practical expedient allowing the use-of-hindsight which would require us to reassess the lease term of its leases based on all facts and circumstances through the effective date and did not elect the practical expedient pertaining to land easements as this is not applicable to our current contract portfolio. See Note 11, Commitments and Contingencies, of the notes to our unaudited condensed consolidated financial statements for additional discussion of our leases and the amounts recognized in these unaudited condensed consolidated financial statements. On January 1, 2019, we adopted ASU 2018 - 08, Not -for-Profit Entities (Topic 958 ): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made. This ASU affects not -for-profit entities and business entities that receive or make contributions of cash. The ASU clarifies and improves the scope and accounting guidance to assist entities in evaluating if those transactions should be accounted for as contributions under the scope of Topic 958 or as an exchange transaction subject to other guidance. The adoption did not have any impact on the financial statements. Recent Accounting Pronouncements: In August 2018, the Financial Accounting Standards Board ("FASB") issued ASU No. 2018 - 13, Fair Value Measurement (Topic 820 ): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , to improve the effectiveness of disclosures. The amendments remove, modify, and add certain disclosure requirements in Topic 820, “Fair Value Measurement.” The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. Furthermore, an entity is permitted to early adopt any removed or modified disclosures upon issuance of the update and delay adoption of the additional disclosures until their effective date. We do not expect this amendment to have a material impact on our consolidated financial statements .

Note 4 - Prepaid Expenses

Note 4 - Prepaid Expenses	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Prepaid Expenses [Text Block]	NOTE 4: Prepaid expenses consisted of the following: June 30, December 31, 2019 2018 Prepaid insurance $ 201,234 $ 160,576 Prepaid research and development 446,143 218,090 Professional services 117,748 110,094 Financial exchange fees 21,000 - Prepaid rent 12,825 - Retainer and security deposits 14,218 16,718 Other - 4,355 Total prepaid expenses $ 813,168 $ 509,833

Note 5 - Research and Developme

Note 5 - Research and Development Tax Rebate Receivable	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 5: On May 23, 2017, 1 2 $0.435 three six June 30, 2019 $387,000 $467,000 $529,000 $616,000, three six June 30, 2018. $203,000 $268,000 six June 30, 2019 2018, June 30, 2019, $406,000 $203,000 December 31, 2018.

Note 6 - Payroll Liabilities

Note 6 - Payroll Liabilities	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	NOTE 6: Payroll liabilities consisted of the following: June 30, 2019 December 31, 2018 Accrued bonuses $ 351,260 $ 697,995 Accrued vacation 165,763 160,740 Accrued payroll 72,422 76,335 Total payroll liabilities $ 589,445 $ 935,070

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7: The Company is authorized to issue a total of 185,000,000 175,000,000 $0.18 10,000,000 $0.001 750,000 $0.001 4,000 $0.001 25,000 $0.001 No no June 30, 2019. 2018 On May 30, 2018, 13,624 13,624 3,869,216 one $4.05 “2018 $12.3 Warrants As of June 30, 2019, 1,070,028 $4.05 May 30, 2022. In March 2019, $11.3 2018 2.8 2.8 No three June 30, 2019. Conversion of Series B Convertible Preferred Stock During the three six June 30, 2019, 26 1,703 7,392 483,823 284

Note 8 - Net Loss Per Share

Note 8 - Net Loss Per Share	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 8: The Company accounts for and discloses net loss per common share in accordance with ASC Topic 260, Earnings Per Share The following table summarizes the Company’s calculation of net loss per common share: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 (as restated) 2019 2018 (as restated) Numerator Net loss $ (7,262,529 ) $ (4,142,577 ) $ (11,335,836 ) $ (6,016,959 ) Deemed dividend attributable to preferred stock - (11,479,308 ) - (11,479,308 ) Net loss attributable to common shareholders $ (7,262,529 ) $ (15,621,885 ) $ (11,335,836 ) $ (17,496,267 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 9,126,153 3,073,803 7,852,907 2,864,033 Net loss per share of common stock, basic and diluted: $ (0.80 ) $ (5.08 ) $ (1.44 ) $ (6.11 ) The following table sets forth the number of weighted average potential common shares excluded from the calculation of net loss per diluted share for the three six June 30, 2019 2018 Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Options to purchase common stock 2,546,295 200,954 1,669,709 187,391 Series B convertible preferred stock 195,448 900,367 326,493 452,671 Warrants to purchase common stock 1,070,028 2,275,808 2,213,396 1,599,074 3,811,771 3,377,129 4,209,598 2,239,136

Note 9 - Income Taxes

Note 9 - Income Taxes	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 9: Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No June 30, 2019 December 31, 2018,

Note 10 - Concentration of Cred

Note 10 - Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 10: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. June 30, 2019 December 31, 2018, $16,423,000 $10,052,000

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 11: Lease Commitments As discussed in Note 3, No. 2016 02, Lease Accounting: 842 , January 1, 2019. January 1, 2019, 840, Leases 842, not Our operating lease assets consist of an office lease and a copier system lease. Our office lease expires in August 2020 October 2021. None three six June 30, 2019, $14,700 $29,400 June 30, 2019, 1.5 12%. As of June 30, 2019, $29,000, $44,000 $12,000 2019, 2020 2021, June 30, 2019, $11,500 three six June 30, 2019 $14,200 $28,800, Litigation and Contingencies We are subject to legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not

Note 12 - Stock Based Compensat

Note 12 - Stock Based Compensation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 12: Stock Option and Incentive Plan On September 28, 2010, 2010 “2010 may 2010 September 2020. No may 2010 10 5,556 2010 May 18, 2016, 11,111 2010 May 9, 2018, 125,000 2010 April 12, 2018, 500,000 2010 May 16, 2019 3,600,000 The following table presents the automatic additions to the 2010 2010 January 1, Number of 2012 2,502 2013 2,871 2014 4,128 2015 5,463 2016 7,257 2017 12,623 2018 106,076 2019 233,862 Total additional shares 374,782 The Company granted options to purchase 3,565,000 three six June 30, 2019 611,688 three six June 30, 2018, No three six June 30, 2019 2018. 271,430 2010 June 30, 2019. Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $5,318,796 $5,594,629 three six June 30, 2019, $179,050 $394,189 three six June 30, 2018 Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 General and administrative $ 3,401,653 $ 137,631 $ 3,626,329 $ 306,424 Research and development 1,917,143 41,419 1,968,300 87,765 Total stock compensation expense $ 5,318,796 $ 179,050 $ 5,594,629 $ 394,189 The fair value of the stock options granted for the six June 30, 2019 2018 Period ended June 30, 2019 2018 Risk free interest rate 2.16%-2.20 % 2.47%-2.71 % Expected term 5.00-5.94 years 5.24-5.57 years Dividend yield - - Expected volatility 107%-126% 109%-126% Options issued and outstanding as of June 30, 2019, 2010 six Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2019 783,383 $ 12.14 - $ - Granted 3,565,000 1.51 - 3,667,300 Forfeited - - - - Expired - - - - Outstanding as of June 30, 2019 4,348,383 3.43 9.54 $ 3,806,650 Exercisable as of June 30, 2019 2,876,409 4.14 9.56 $ 2,841,125 Vested and expected to vest 4,348,383 $ 3.43 9.54 $ 3,806,650 At June 30, 2019, 1,471,974 $3,148,286. 1.15 2018 On June 27, 2018, 2,300,000 700,000 2010 2010 January 13, 2019, The Liability Options were exercisable for shares of common stock at an exercise price of $2.38 ten not not The Liability Options were subject to vesting requirements. Twenty- five 50% two 25% January 13, 2019, January 13, 2019, 1,125,000 Compensation costs associated with the Liability Options were initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria were achieved for options that vest based on performance. Compensation cost was remeasured each period based on the market value of our underlying stock until award vesting or settlement. At the time of cancellation, the fair value of Liability Options at January 13, 2019, January 13, 2019 Risk free interest rate 2.53 % Expected term (in years) 4.50-5.00 Stock price $ 1.36 Dividend yield - Expected volatility 121.0-123.0 % As a result of the cancellation of these options in the first 2019, $1,741,919, three March 31, 2019 six June 30, 2019: General and administrative $ 1,074,183 Research and development 667,736 Total stock compensation expense $ 1,741,919 Also on January 13, 2019, 2,300,000 800,000 “2019 2019 $1.36 not 2010 January 13, 2019, 2019 2010 2019 not 2010 2018 2019 not 2019 The above actions were unanimously approved by the disinterested members of the Board of Directors. The above actions were intended to eliminate the Company’s potential liability associated with the net cash exercise provision of the Liability Options, and to allow the stockholders of the Company the opportunity to vote on the Amended Plan, which includes shares issuable upon exercise of the 2019 May 16, 2019, 2019 Accounting Treatment Awards offered under a plan that are subject to shareholder approval are not may not 2019 2019 not 718. not no January 13, 2019, $1,741,919 2018 $3,151,944 May 16, 2019, 2019 2019 718 June 30, 2019. $4,959,277 second 2019 2019

Note 13 - Restatement to Previo

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Reclassifications [Text Block]	NOTE 13: The Company corrected an inadvertent error in the calculation of the deemed dividend on Series B convertible preferred stock in the financial statements for the three six June 30, 2018 10 August 13, 2018 ( 10 May 2018 10 not not three six June 30, 2018 $4,782,100, $11,479,308. three six June 30, 2018 $8,924,677 $10,799,059, $15,621,885 $17,496,267. three six June 30, 2018 $2.90 $3.77, $5.08 $6.11. not

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2018. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three six June 30, 2019, not may December 31, 2019.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements: In the first 2019, No. 2016 02, Lease Accounting 842 : (" 842 ") $101,000 not not 840. 2018 10 840. not not not not not not not 11, Commitments and Contingencies, On January 1, 2019, 2018 08, Not 958 not 958 not Recent Accounting Pronouncements: In August 2018, No. 2018 13, Fair Value Measurement (Topic 820 820, 3 December 15, 2019. not consolidated financial statements

Note 4 - Prepaid Expenses (Tabl

Note 4 - Prepaid Expenses (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	June 30, December 31, 2019 2018 Prepaid insurance $ 201,234 $ 160,576 Prepaid research and development 446,143 218,090 Professional services 117,748 110,094 Financial exchange fees 21,000 - Prepaid rent 12,825 - Retainer and security deposits 14,218 16,718 Other - 4,355 Total prepaid expenses $ 813,168 $ 509,833

Note 6 - Payroll Liabilities (T

Note 6 - Payroll Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2019 December 31, 2018 Accrued bonuses $ 351,260 $ 697,995 Accrued vacation 165,763 160,740 Accrued payroll 72,422 76,335 Total payroll liabilities $ 589,445 $ 935,070

Note 8 - Net Loss Per Share (Ta

Note 8 - Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2019 2018 (as restated) 2019 2018 (as restated) Numerator Net loss $ (7,262,529 ) $ (4,142,577 ) $ (11,335,836 ) $ (6,016,959 ) Deemed dividend attributable to preferred stock - (11,479,308 ) - (11,479,308 ) Net loss attributable to common shareholders $ (7,262,529 ) $ (15,621,885 ) $ (11,335,836 ) $ (17,496,267 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 9,126,153 3,073,803 7,852,907 2,864,033 Net loss per share of common stock, basic and diluted: $ (0.80 ) $ (5.08 ) $ (1.44 ) $ (6.11 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Options to purchase common stock 2,546,295 200,954 1,669,709 187,391 Series B convertible preferred stock 195,448 900,367 326,493 452,671 Warrants to purchase common stock 1,070,028 2,275,808 2,213,396 1,599,074 3,811,771 3,377,129 4,209,598 2,239,136

Note 12 - Stock Based Compens_2

Note 12 - Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	January 1, Number of 2012 2,502 2013 2,871 2014 4,128 2015 5,463 2016 7,257 2017 12,623 2018 106,076 2019 233,862 Total additional shares 374,782
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 General and administrative $ 3,401,653 $ 137,631 $ 3,626,329 $ 306,424 Research and development 1,917,143 41,419 1,968,300 87,765 Total stock compensation expense $ 5,318,796 $ 179,050 $ 5,594,629 $ 394,189 General and administrative $ 1,074,183 Research and development 667,736 Total stock compensation expense $ 1,741,919
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Period ended June 30, 2019 2018 Risk free interest rate 2.16%-2.20 % 2.47%-2.71 % Expected term 5.00-5.94 years 5.24-5.57 years Dividend yield - - Expected volatility 107%-126% 109%-126% January 13, 2019 Risk free interest rate 2.53 % Expected term (in years) 4.50-5.00 Stock price $ 1.36 Dividend yield - Expected volatility 121.0-123.0 %
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2019 783,383 $ 12.14 - $ - Granted 3,565,000 1.51 - 3,667,300 Forfeited - - - - Expired - - - - Outstanding as of June 30, 2019 4,348,383 3.43 9.54 $ 3,806,650 Exercisable as of June 30, 2019 2,876,409 4.14 9.56 $ 2,841,125 Vested and expected to vest 4,348,383 $ 3.43 9.54 $ 3,806,650

Note 2 - Liquidity and Capita_2

Note 2 - Liquidity and Capital Resources (Details Textual) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Net Income (Loss) Attributable to Parent, Total	$ (7,262,529)	$ (4,073,307)	$ (4,142,577)	$ (1,874,382)	$ (11,335,836)	$ (6,016,959)
Net Cash Provided by (Used in) Operating Activities, Total					(4,651,051)	(4,219,793)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	17,058,527		$ 15,236,736		17,058,527	$ 15,236,736	$ 10,380,493
Working Capital	$ 17,400,000				$ 17,400,000

Note 3 - Summary of Accountin_2

Note 3 - Summary of Accounting Policies (Details Textual) - USD ($)	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease, Liability, Total		$ 101,000
Operating Lease, Right-of-Use Asset	$ 75,822	$ 101,000

Note 4 - Prepaid Expenses - Sch

Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Prepaid insurance	$ 201,234	$ 160,576
Prepaid research and development	446,143	218,090
Professional services	117,748	110,094
Financial exchange fees	21,000
Prepaid rent	12,825
Retainer and security deposits	14,218	16,718
Other		4,355
Total prepaid expenses	$ 813,168	$ 509,833

Note 5 - Research and Develop_2

Note 5 - Research and Development Tax Rebate Receivable (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	May 23, 2017
Research and Development Expense, Total	$ 2,611,948	$ 1,467,736	$ 4,063,184	$ 1,938,712
Increase (Decrease) in Research and Development Tax Rebate Receivable			(111,792)	267,734
Research and Development Tax Rebate Receivable	406,306		406,306		$ 518,098
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Cash Rebate per Dollar						$ 0.435
Research and Development Expense, Total	387,000	$ 529,000	467,000	616,000
Increase (Decrease) in Research and Development Tax Rebate Receivable			203,000	$ 268,000
Research and Development Tax Rebate Receivable	$ 406,000		$ 406,000		$ 203,000

Note 6 - Payroll Liabilities -

Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accrued bonuses	$ 351,260	$ 697,995
Accrued vacation	165,763	160,740
Accrued payroll	72,422	76,335
Total payroll liabilities	$ 589,445	$ 935,070

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Details Textual) - USD ($)	May 30, 2018	Mar. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Number of Shares Authorized to Issue			185,000,000		185,000,000
Common Stock, Shares Authorized			175,000,000		175,000,000		175,000,000
Common Stock, Par or Stated Value Per Share			$ 0.18		$ 0.18		$ 0.18
Preferred Stock, Shares Authorized			10,000,000		10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share			$ 0.001		$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total			676		676		2,379
Class of Warrant or Right, Outstanding			1,070,028		1,070,028
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 4.05		$ 4.05
Proceeds from Warrant Exercises		$ 11,300,000			$ 11,336,710
Class of Warrant or Right, Exercised During Period			0	2,800,000
Stock Issued During Period, Shares, Warrant Exercised				2,800,000
Preferred Stock, Shares Outstanding, Ending Balance			676		676		2,379
Conversion of Series B Convertible Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted			26		1,703
Conversion of Stock, Shares Issued			7,392		483,823
Convertible Preferred Stock, Shares Issued upon Conversion			284		284
The 2018 Subscription Rights Offering [Member]
Number of Units Sold	13,624
Proceeds from Issuance of Stock units	$ 12,300,000
The 2018 Subscription Rights Offering [Member] | The 2018 Warrants [Member]
Class of Warrant or Right, Outstanding	3,869,216
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.05
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized			750,000		750,000
Preferred Stock, Par or Stated Value Per Share			$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total			0		0
Preferred Stock, Shares Outstanding, Ending Balance			0		0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized			4,000		4,000
Preferred Stock, Par or Stated Value Per Share			$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total							0
Preferred Stock, Shares Outstanding, Ending Balance							0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized			25,000		25,000
Preferred Stock, Par or Stated Value Per Share			$ 0.001		$ 0.001
Series B Convertible Preferred Stock [Member] | The 2018 Subscription Rights Offering [Member]
Stock Issued During Period, Shares, New Issues	13,624

Note 8 - Net Loss Per Share - S

Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Net loss	$ (7,262,529)	$ (4,073,307)	$ (4,142,577)	$ (1,874,382)	$ (11,335,836)	$ (6,016,959)
Deemed dividend attributable to preferred stock			(11,479,308)			(11,479,308)
Net loss attributable to common shareholders	$ (7,262,529)		$ (15,621,885)		$ (11,335,836)	$ (17,496,267)
Net loss per share of common stock, basic and diluted: (in dollars per share)	$ (0.80)		$ (5.08)		$ (1.44)	$ (6.11)

Note 8 - Net Loss Per Share -_2

Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Number of potential common shares excluded (in shares)	3,811,771	3,377,129	4,209,598	2,239,136
Share-based Payment Arrangement, Option [Member]
Number of potential common shares excluded (in shares)	2,546,295	200,954	1,669,709	187,391
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	195,448	900,367	326,493	452,671
Warrant [Member]
Number of potential common shares excluded (in shares)	1,070,028	2,275,808	2,213,396	1,599,074

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accrued Income Taxes, Total	$ 0	$ 0

Note 10 - Concentration of Cr_2

Note 10 - Concentration of Credit Risk (Details Textual) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Cash, Uninsured Amount	$ 16,423,000	$ 10,052,000

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual)	3 Months Ended	6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)
Operating Lease, Expense	$ 14,700	$ 29,400
Operating Lease, Weighted Average Remaining Lease Term	1 year 182 days	1 year 182 days
Operating Lease, Weighted Average Discount Rate, Percent	12.00%	12.00%
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 29,000	$ 29,000
Lessee, Operating Lease, Liability, Payments, Due Year Two	44,000	44,000
Lessee, Operating Lease, Liability, Payments, Due Year Three	12,000	12,000
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	11,500	11,500
Operating Lease, Payments	$ 14,200	$ 28,800

Note 12 - Stock Based Compens_3

Note 12 - Stock Based Compensation (Details Textual) - USD ($)	May 16, 2019	Jan. 13, 2019	Jun. 27, 2018	May 09, 2018	Apr. 12, 2018	May 18, 2016	Sep. 28, 2010	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement, Expense								$ 5,318,796		$ 179,050	$ 5,594,629	$ 394,189
Adjustments to Additional Paid in Capital, Transfer of Stock-based Compensation Liability Upon Option Cancellation		$ 3,151,944							$ 3,151,944
Share-based Payment Arrangement, Option [Member] | Executive Officer [Member]
Share-based Payment Arrangement, Expense								$ 4,959,277
Liability Options [Member]
Share-based Payment Arrangement, Expense		$ 1,741,919
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance		1,125,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 2.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Liability Options [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			25.00%
Liability Options [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			2 years
Liability Options [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			25.00%
Liability Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			2,300,000
Liability Options [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			700,000
The 2019 Options [Member[
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 1.36
The 2019 Options [Member[ | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,300,000
The 2019 Options [Member[ | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		800,000
The 2010 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Period for Granting Shares							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	3,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								3,565,000		611,688	3,565,000	611,688
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period								0		0	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant								271,430			271,430
Share-based Payment Arrangement, Expense								$ 5,318,796		$ 179,050	$ 5,594,629	$ 394,189
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance								1,471,974			1,471,974
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$ 1.51
The 2010 Stock Option and Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							5,556
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized				125,000	500,000	11,111
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount								$ 3,148,286			$ 3,148,286
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition											1 year 54 days

Note 12 - Stock Based Compens_4

Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) - shares	6 Months Ended	12 Months Ended							90 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2019
The 2010 Stock Option and Incentive Plan [Member]
Total additional shares (in shares)	233,862	106,076	12,623	7,257	5,463	4,128	2,871	2,502	374,782

Note 12 - Stock Based Compens_5

Note 12 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)	Jan. 13, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Stock compensation expense		$ 5,318,796	$ 179,050	$ 5,594,629	$ 394,189
Total stock compensation expense		5,318,796	179,050	5,594,629	394,189
Liability Options [Member]
Stock compensation expense	$ 1,741,919
Total stock compensation expense	1,741,919
General and Administrative Expense [Member]
Stock compensation expense		3,401,653	137,631	3,626,329	306,424
Total stock compensation expense		3,401,653	137,631	3,626,329	306,424
General and Administrative Expense [Member] | Liability Options [Member]
Stock compensation expense	1,074,183
Total stock compensation expense	1,074,183
Research and Development Expense [Member]
Stock compensation expense		1,917,143	41,419	1,968,300	87,765
Total stock compensation expense		$ 1,917,143	$ 41,419	$ 1,968,300	$ 87,765
Research and Development Expense [Member] | Liability Options [Member]
Stock compensation expense	667,736
Total stock compensation expense	$ 667,736

Note 12 - Stock Based Compens_6

Note 12 - Stock Based Compensation - Valuation Assumptions (Details) - $ / shares	Jan. 13, 2019	Jun. 30, 2019
Liability Options [Member]
Stock price (in dollars per share)	$ 1.36
Minimum [Member] | Liability Options [Member]
Risk free interest rate	2.53%
Minimum [Member] | Share-based Payment Arrangement, Option [Member]
Expected volatility		107126.00%
Maximum [Member] | Share-based Payment Arrangement, Option [Member]
Expected volatility		109126.00%

Note 12 - Stock Based Compens_7

Note 12 - Stock Based Compensation - Stock Option Activity (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Expired (in shares)
Expired, weighted average exercise price per share (in dollars per share)
The 2010 Stock Option and Incentive Plan [Member]
Outstanding, shares (in shares)			783,383
Outstanding, weighted average exercise price per share (in dollars per share)			$ 12.14
Granted, shares (in shares)	3,565,000	611,688	3,565,000	611,688
Granted, weighted average exercise price per share (in dollars per share)			$ 1.51
Granted			$ 3,667,300
Forfeited, shares (in shares)
Forfeited, weighted average exercise price per share (in dollars per share)
Outstanding, shares (in shares)	4,348,383		4,348,383
Outstanding, Weighted average exercise price per share (in dollars per share)	$ 3.43		$ 3.43
Outstanding, weighted average contractual life remaining in years (Year)			9 years 197 days
Outstanding, aggreate instrinsic value	$ 3,806,650		$ 3,806,650
Exercisable, shares (in shares)	2,876,409		2,876,409
Exercisable, Weighted average exercise price per share (in dollars per share)	$ 4.14		$ 4.14
Exercisable, weighted average contractual life remaining in years (Year)			9 years 204 days
Exercisable, aggreate instrinsic value	$ 2,841,125		$ 2,841,125
Vested and expected to vest, shares (in shares)	4,348,383		4,348,383
Vested and expected to vest, Weighted average exercise price per share (in dollars per share)	$ 3.43		$ 3.43
Vested and expected to vest, weighted average contractual life remaining in years (Year)			9 years 197 days
Vested and expected to vest, aggreate instrinsic value	$ 3,806,650		$ 3,806,650

Note 13 - Restatement to Prev_2

Note 13 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Preferred Stock, Deemed Dividend		$ 11,479,308		$ 11,479,308
Net Income (Loss) Available to Common Stockholders, Basic, Total	$ (7,262,529)	$ (15,621,885)	$ (11,335,836)	$ (17,496,267)
Earnings Per Share, Basic and Diluted, Total	$ (0.80)	$ (5.08)	$ (1.44)	$ (6.11)
Series B Convertible Preferred Stock [Member]
Deemed Dividend on Series B Convertible Preferred Stock		$ 11,479,308
Previously Reported [Member]
Net Income (Loss) Available to Common Stockholders, Basic, Total		$ (8,924,677)		$ (10,799,059)
Earnings Per Share, Basic and Diluted, Total		$ (2.90)		$ (3.77)
Previously Reported [Member] | Series B Convertible Preferred Stock [Member]
Preferred Stock, Deemed Dividend		$ 4,782,100